Clinical Trial Update: NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders [Phase 2]

View source ↗

Summary

Phase 2 trial update of an allogeneic hematopoietic cell transplant in hematologic cancers/disorders; status completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Fanconi Anemia
• Leukemia
• Lymphoma
• Multiple Myeloma and Plasma Cell Neoplasm
• Myelodysplastic Myeloproliferative Diseases
• Myelodysplastic Syndromes
• Myeloproliferative Disorders

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2020-02-10